RE:AGMDiscussions concerning out-licensing a PGX complex are underway right now with serious potential partners. The goal is still a license by the end of the year. Bioavailability, given the impressive results from the University of Alberta, is the unique selling point. CoQ10 is a $4 billion market.
What could a deal be worth given CZO's bioavailaiblity results against the gold standard in a $4 billion market? How could a deal validate PGX more broadly as the fibrosis opportunity also potentially reaches a 'go' decision concerning clinical trials?